Immutep Limited

Informe acción NasdaqGM:IMMP

Capitalización de mercado: US$59.2m

Immutep Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Immutep de 25.8% y 47% por año respectivamente. Se prevé que el BPA crezca en un 43.7% al año. Se espera que la rentabilidad financiera sea de -15.7% en 3 años.

Información clave

25.8%

Tasa de crecimiento de los beneficios

43.71%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs25.2%
Tasa de crecimiento de los ingresos47.0%
Rentabilidad financiera futura-15.72%
Cobertura de analistas

Good

Última actualización01 May 2026

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Seeking Alpha • May 08

Immutep Limited: Surging On Positive Head And Neck Data

Summary Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues. Despite promising phase 2 data, the fate of eftilagimod remains uncertain, with future trials and FDA discussions critical for potential accelerated approval. The positive TACTI-003 readout strengthens my "Buy" sentiment, though risks remain in this challenging cancer treatment landscape. Read the full article on Seeking Alpha
Seeking Alpha • Jan 28

Immutep Limited: Continuing To Make The Case For Eftilagimod

Summary Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics. Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer and soft tissue sarcoma, enhancing the drug's potential. Financially, IMMP has a cash runway at least to 2026, supporting ongoing and future clinical trials without immediate funding concerns. Recent clinical data suggest meaningful advancements in LAG-3 therapeutics, reinforcing the investment thesis and highlighting IMMP's undervalued status. Read the full article on Seeking Alpha
Seeking Alpha • Nov 15

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Summary Positive results from phase 1 INSIGHT-003 study, using eftilagimod alpha in combination with KEYTRUDA and chemotherapy in treating first-line metastatic non-squamous NSCLC patients. Additional data from the phase 1 INSIGHT-003 study is expected in 2025, with plans to initiate a phase 3 TACTI-004 study targeting the same patient population. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031. Results from the phase 2b TACTI-003 study, using efti + KEYTRUDA to treat 1st-line recurrent/metastatic head and neck squamous cell carcinoma, expected in 2025; OS set as primary endpoint. Read the full article on Seeking Alpha
Seeking Alpha • Jul 15

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Summary Immutep Limited achieved positive results in the phase 2b study, using efti + Keytruda for the treatment of patients with 1st-line head and neck squamous cell carcinoma; Both PD-L1 positive and negative patients. Company to meet with FDA to be in a position to initiate a phase 3 study using efti + Keytruda for the treatment of patients with 1st-line HNSCC. Merck supply collaboration agreement in place to advance phase 3 study, using efti + Keytruda + chemotherapy for the treatment of 1stline NSCLC patients. Keytruda had become one of the top-selling drugs in 2023, with sales exceeding $25 billion; Efti has shown to help double several efficacy measures when added to Keytruda. Read the full article on Seeking Alpha
Seeking Alpha • May 01

Immutep: Realizing The Expected Catalysts, With More To Come

Summary Immutep Limited is focused on developing novel treatments targeting LAG3, an immune checkpoint, for various tumor types. The company's pipeline includes eftilagimod, which has shown promising response rates in thoracic malignancies. Immutep should have sufficient funding for 9–10 quarters of research and has demonstrated promising early signals of efficacy and safety. Read the full article on Seeking Alpha
Seeking Alpha • Oct 04

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

The U.S. Food and Drug Administration (FDA) granted fast track designation to Immutep's (NASDAQ:IMMP) eftilagimod alpha (IMP321) in combination with Merck's (NYSE:MRK) Keytruda (pembrolizumab) to treat first line non-small cell lung cancer (NSCLC). The combo was granted the status for initial treatment of patients with stage 3B/4 NSCLC expressing PD-L1 Tumor Proportion Score ≥1%, not amenable to EGFR/ALK based therapy, due to data from a phase 2 trial called TACTI-002/KEYNOTE-798, the company said in an Oct. 4 press release. "Efti also offers a chemotherapy-free option for NSCLC patients in need of less toxic and more durable solutions," said Immutep CEO Marc Voigt. The efti/Keytruda combo had previously received the FDA's fast track status in April 2021 as a first-line treatment for recurrent or metastatic Head and Neck Squamous Cell Carcinoma. IMMP +7.21% to $1.71 premarket Oct. 4
Seeking Alpha • Sep 23

Immutep secures €1.8M cash in French government's research tax credit

Immutep (NASDAQ:IMMP) announced Friday it has received €1.8M cash from the French government in research and development tax incentive payment. The incentive comes under the government's research tax credit scheme under which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure. The biotech firm said it intends to use the proceeds to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761. Stock is up 5% in pre-market trading. Earlier: Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo
Seeking Alpha • Aug 30

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Immutep (NASDAQ:IMMP) said the Japanese Patent Office granted a new patent for eftilagimod alpha in combination with a PD-1 pathway inhibitor. The patent titled, 'Combined Preparations for the Treatment of Cancer or Infection' protects intellectual property related to combined therapeutic preparations consisting of  immunotherapy candidate eftilagimod alpha and an anti-PD-(L)1 antibody, the company said in an Aug. 30 press release. The company added that the claims are also directed to related methods of use in treating cancer and infection. "This is especially meaningful when coupled with the very promising data we have reported from TACTI-002 in three cancer indications, along with the initiation of TACTI-003 in the past 12 months," said Immutep CEO Marc Voigt. The patent is expected to expire Jan. 8, 2036.
Seeking Alpha • Jul 06

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Immutep (NASDAQ:IMMP) said it received a patent from the Japanese Patent Office related to its pre-clinical product candidate IMP761. The patent number number 7074341 titled 'Anti-LAG-3 Antibodies' is related to pharmaceutical compositions comprising IMP761 and the use of the compositions to treat T-cell mediated inflammatory and autoimmune diseases, according to the company's July 6 press release. The patent will expiry on Sept. 1, 2036.
Seeking Alpha • Jun 12

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Immutep has been developing anti-LAG3 compounds for over a decade. Recent approval of the first such compound from BMY was a watershed event. However, IMMP has a long way to go.
Seeking Alpha • Mar 21

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

FDA approval of Bristol Myers Opdualag/relatlimab anti-LAG3 carries positive implications for LAG3 pure-play Immutep’s entire pipeline. From an anti-LAG3 perspective, the FDA approval is directly positive for Immutep's recently unveiled oral, small molecule anti-LAG3 program and its out-licensed anti-LAG3 program to Novartis. Like anti-PD1 (Keytruda, Opvido) & anti-CLTA4 (Yervoy), LAG3 may be a key checkpoint in oncology. Yet, unlike PD1/CTLA4, LAG3 is unique in that both its activation & inhibition kills cancer. This relatively unknown pure-play on the emerging checkpoint LAG3 (Lymphocyte Activating Gene-3) has collaborations with Novartis, Merck, Pfizer, Merck KGaA, GlaxoSmithKline, EOC Pharma, Labcorp, etc. As its clinical data continues to strengthen, like it consistently has over the past few years, Immutep is seemingly well situated for strategic deals or its potential acquisition.
Seeking Alpha • Jun 21

Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%

Immutep (IMMP) has signed an agreement to commence a new Phase I trial, called INSIGHT-003, to evaluate the combination of lead product candidate eftilagimod alpha (“efti” or “IMP321”) in conjunction with an existing approved standard of care therapy consisting of a chemotherapy agent and an anti-PD-1 therapy. INSIGHT-003 will be run as an amendment to the protocol of the ongoing INSIGHT trial as the third arm (Stratum C) with Prof. Dr. Salah-Eddin Al-Batran as lead investigator. Up to 20 patients

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:IMMP - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
6/30/20285-65-77-625
6/30/20273-52-58-546
6/30/202619-55-56-536
12/31/20258-84-62-62N/A
9/30/20256-73-62-62N/A
6/30/20255-61-62-62N/A
3/31/20255-53-54-53N/A
12/31/20245-44-46-45N/A
9/30/20244-43-41-40N/A
6/30/20244-43-36-35N/A
3/31/20244-42-39-38N/A
12/31/20234-41-42-42N/A
9/30/20234-40-39-39N/A
6/30/20234-40-35-35N/A
3/31/20234-38-33-33N/A
12/31/20224-37-30-30N/A
9/30/20225-34-30-30N/A
6/30/20225-32-30-30N/A
3/31/20224-29-25-25N/A
12/31/20214-26-20-20N/A
9/30/20214-28-19-19N/A
6/30/20214-30-18-18N/A
3/31/20215-29-16-16N/A
12/31/20206-27-15-15N/A
9/30/202010-20-13-13N/A
6/30/202014-13-11-11N/A
3/31/202013-15-13-13N/A
12/31/201913-16-14-14N/A
9/30/20199-17N/A-15N/A
6/30/20196-18N/A-15N/A
3/31/20195-18N/A-13N/A
12/31/20185-17N/A-10N/A
9/30/20186-15N/A-9N/A
6/30/20187-13N/A-8N/A
3/31/20186-12N/A-8N/A
12/31/20177-10N/A-8N/A
9/30/20175-9N/A-8N/A
6/30/20174-9N/A-9N/A
3/31/20173-10N/A-8N/A
12/31/20162-10N/A-9N/A
9/30/20162-36N/A-10N/A
6/30/20162-62N/A-11N/A
3/31/20162-71N/A-10N/A
12/31/20151-82N/A-8N/A
9/30/20151-57N/A-8N/A
6/30/20151-32N/A-8N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que IMMP siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que IMMP siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que IMMP siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (47% al año) de IMMP crezcan más rápidamente que los del mercado US (11.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (47% al año) de IMMP crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: IMMP se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/26 03:22
Precio de las acciones al final del día2026/05/26 00:00
Beneficios2025/12/31
Ingresos anuales2025/06/30

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Immutep Limited está cubierta por 14 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Melissa BensonBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
Dylan DupuisB. Riley Securities, Inc.